SS-31
Also called SS31, elamipretide, MTP-131
SS-31 is a mitochondria specialist.
Studied in people, in small numbers. The ranges below lean mostly on community-reported dosing and results — what people run, and what they say happened.
- Energy
- Longevity & anti-aging
- Recovery & injury
The quick answer
SS-31 is a mitochondria specialist. It concentrates right inside your cells' power plants and helps stabilize the machinery that makes energy - which is why it's studied for fatigue and the kind of tiredness that comes from cells not making enough fuel.
Expect a gradual, stacking effect rather than a same-day lift: people most often notice better exercise recovery and mental endurance around the three-to-four-week mark, and many run it in cycles. Honest note: the mechanism is compelling and there are real human trials - but several key ones didn't hit their targets, so it's best thought of as promising and still investigational, not a sure thing.
Why people use it
⚡ Recharges cellular energy; 🔋 Less fatigue; 🛡️ Cuts oxidative stress; 🏃 Better endurance and recovery; ⏳ Supports age-related energy
What people report using
These are ranges other people have reported running. They are here so you can see what has actually been done — they are not medical advice and not a recommendation for you.
Energy
- How often
- Mon–Fri
- Route
- subcutaneous
- Where this comes from
- Small human studies
One reported protocol runs it Monday, Tuesday, Wednesday, Friday and Saturday.
Energy
- How often
- Every day, morning
- Route
- subcutaneous
- Where this comes from
- Small human studies
Where it does show up, it is described as mental clarity and a better foundation rather than energy.
Longevity & anti-aging
- How often
- Every day, morning
- Route
- subcutaneous
- Where this comes from
- Small human studies
Where it does show up, it is described as mental clarity and a better foundation rather than energy.
50mg vial + 3ml BAC water = 16.67mg/ml. Titrate 1mg (6u) to 5mg (30u). Daily AM, cycled.
Work out your own units on the reconstitution calculator — the most common serious mistake in this area is arithmetic, not chemistry.
What to expect, and when
- First thing people notice
- Weeks 1–2 (energy)
- When it gets real
- Weeks 3–4 (endurance)
- Where it peaks
- Weeks 6–8 (recovery)
- Patience needed
- Medium - cumulative
- Weeks 1–2Subtle lift in energy
SS-31 concentrates in the inner mitochondrial membrane by binding cardiolipin, where it is studied for stabilising electron transport and improving ATP production. In a randomized trial, a single infusion rapidly raised in-vivo mitochondrial energetic capacity in older adults' skeletal muscle, so an early, subtle energy lift is mechanistically plausible. Early sensations are subjective and easily confounded.
- Weeks 3–4Endurance and exercise tolerance
By the third to fourth week, users on cumulative protocols often report better endurance and exercise tolerance, consistent with the peptide's high concentration in skeletal-muscle mitochondria. Preclinical and early-phase work has explored improvements in muscle energetics and functional capacity. Note that these are research-context signals, not guaranteed personal outcomes.
- Weeks 5–6Recovery between efforts
Improved recovery between training sessions is a commonly reported cumulative effect, in line with the idea that better mitochondrial coupling lowers oxidative stress. Some early-phase trials suggested functional gains, though this remains an area of active and mixed investigation. Individual response varies widely.
- Weeks 6–8Peak cumulative feel
Users describe the fullest sense of benefit accumulating around six to eight weeks. It is important to be honest here: the pivotal Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet its primary walk-distance or fatigue endpoints, even though earlier and subgroup data were more encouraging. SS-31 is investigational, and its longevity and performance uses remain unproven.
Elamipretide is investigational and not FDA-approved; its pivotal Phase 3 mitochondrial-myopathy trial missed its primary endpoints, so human efficacy for energy and performance remains unestablished.
Side effects, and what people do about them
Well tolerated. Most people notice little beyond the odd injection-site reaction or a mild headache. It's used thoughtfully in courses rather than continuously, which keeps it easy.
Go deeper
Open these only if you want them.
How it actually works
Elamipretide - a four-amino-acid peptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, the lipid that gives cristae their shape. By stabilising cardiolipin it keeps the cristae folded properly, which keeps the electron transport chain efficient and reduces electron leak.
It is a structural intervention rather than a signalling one, and that is the cleanest way to think about combining it. MOTS-c activates AMPK - a signal telling the cell what to do. This one improves the machinery that carries the instruction out. They are complementary in a way that two AMPK activators would not be.
What people report, in full
SS-31 is a favourite of endurance athletes and longevity biohackers, marketed around protecting the mitochondria. Roughly half to sixty percent report better energy and endurance in the first couple of weeks; the rest notice little, and the community suspects that comes down to your mitochondrial starting point - older folks and athletes tend to respond more than young, healthy people. The one thing that does come up is the injection site - itching, a little redness, sometimes a firm spot that fades over a day or two. That squares with the trial data on the same molecule: in a 24-week study every participant noticed something at the site, all of it mild or moderate, and one person in twenty-one stopped over it - and that was at 40mg a day, ten times what people run here. Rotating sites and injecting slowly is what people say sorts it. The catch is that the benefit is hard to measure at home. It's often stacked with NAD+ and MOTS-c as a "mitochondrial trio."
Worth knowing
The trials are real. They were not asking the question most people are asking when they come looking for this one.
Sources and review
This record is built on what the wider community reports doing and experiencing, summarised above. No counted dataset has been attached to this compound yet — when one is published, it goes here with its numbers.
MMPOWER-3 — Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: a randomized clinical trial. Neurology 2023. PMID 37268435.Did not improve the six-minute walk test or fatigue endpoints.
These references were located by literature search and recorded as the primary sources behind this record. The publishers block automated retrieval, so they are pointers to the right papers rather than quotations we have checked line by line. They are replaced as we read them properly.
Last reviewed 2026-09-06.
People also look at
Still not sure?
Ask it the way you would ask a person. Follow-up questions are the point — it remembers what you already said.
Ask about SS-31